Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
Launched by WEST CHINA HOSPITAL · Aug 12, 2019
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called tacrolimus to see how well it works for treating two types of skin growths: superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA). The researchers are using different strengths of a cream that contains tacrolimus, which is applied directly to the skin, to assess its effectiveness and safety for patients. The trial is open to people of all ages, from newborns to older adults, as long as they have been diagnosed with KHE or TA and do not have an allergy to tacrolimus.
Participants in this trial can expect to apply the tacrolimus cream as directed by the study team and attend follow-up visits to monitor their progress. The goal is to determine if this treatment can help reduce or improve their skin conditions. It’s important to know that this study is currently looking for volunteers, and if you or someone you know has one of these skin conditions, this trial could be an option to consider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
- Exclusion Criteria:
- • Hypersensitivity to Tacrolimus Mucosal Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
About West China Hospital
West China Hospital, affiliated with Sichuan University, is a leading medical institution renowned for its comprehensive healthcare services, advanced research initiatives, and commitment to medical education. As a prominent clinical trial sponsor, the hospital leverages its extensive resources and expertise to facilitate innovative research in various therapeutic areas. With a focus on improving patient outcomes and advancing medical knowledge, West China Hospital collaborates with various stakeholders to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. Its state-of-the-art facilities and multidisciplinary teams ensure the successful execution of trials, contributing significantly to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, China
Patients applied
Trial Officials
Yi Ji
Principal Investigator
West China Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials